Jama Oncology最新文献

筛选
英文 中文
Change of Article Status to Open Access. 将文章状态改为开放存取。
IF 28.4 1区 医学
Jama Oncology Pub Date : 2024-11-14 DOI: 10.1001/jamaoncol.2024.5689
{"title":"Change of Article Status to Open Access.","authors":"","doi":"10.1001/jamaoncol.2024.5689","DOIUrl":"10.1001/jamaoncol.2024.5689","url":null,"abstract":"","PeriodicalId":48661,"journal":{"name":"Jama Oncology","volume":" ","pages":""},"PeriodicalIF":28.4,"publicationDate":"2024-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11565291/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142630737","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Concerns Regarding Sample Size and Credibility of Progression-Free Survival Results. 对样本量和无进展生存期结果可信度的担忧。
IF 28.4 1区 医学
Jama Oncology Pub Date : 2024-11-14 DOI: 10.1001/jamaoncol.2024.5154
Xiaoling Xu, Lisha Ye, Yaping Xu
{"title":"Concerns Regarding Sample Size and Credibility of Progression-Free Survival Results.","authors":"Xiaoling Xu, Lisha Ye, Yaping Xu","doi":"10.1001/jamaoncol.2024.5154","DOIUrl":"https://doi.org/10.1001/jamaoncol.2024.5154","url":null,"abstract":"","PeriodicalId":48661,"journal":{"name":"Jama Oncology","volume":" ","pages":""},"PeriodicalIF":28.4,"publicationDate":"2024-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142630738","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Concerns Regarding Sample Size and Credibility of Progression-Free Survival Results-Reply. 关于样本量和无进展生存期结果可信度的担忧--回复。
IF 28.4 1区 医学
Jama Oncology Pub Date : 2024-11-14 DOI: 10.1001/jamaoncol.2024.5151
Song Dong, Hong-Hong Yan, Yi-Long Wu
{"title":"Concerns Regarding Sample Size and Credibility of Progression-Free Survival Results-Reply.","authors":"Song Dong, Hong-Hong Yan, Yi-Long Wu","doi":"10.1001/jamaoncol.2024.5151","DOIUrl":"https://doi.org/10.1001/jamaoncol.2024.5151","url":null,"abstract":"","PeriodicalId":48661,"journal":{"name":"Jama Oncology","volume":" ","pages":""},"PeriodicalIF":28.4,"publicationDate":"2024-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142630833","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Toripalimab For Extensive-Stage Small Cell Lung Cancer. 托利帕利单抗治疗广泛期小细胞肺癌
IF 28.4 1区 医学
Jama Oncology Pub Date : 2024-11-14 DOI: 10.1001/jamaoncol.2024.4958
Ayse Ece Cali Daylan, Daniel Morgensztern, Saiama N Waqar
{"title":"Toripalimab For Extensive-Stage Small Cell Lung Cancer.","authors":"Ayse Ece Cali Daylan, Daniel Morgensztern, Saiama N Waqar","doi":"10.1001/jamaoncol.2024.4958","DOIUrl":"https://doi.org/10.1001/jamaoncol.2024.4958","url":null,"abstract":"","PeriodicalId":48661,"journal":{"name":"Jama Oncology","volume":" ","pages":""},"PeriodicalIF":28.4,"publicationDate":"2024-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142630835","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
PD-L1 Expression for Tailoring Treatment in Advanced Melanoma-It Is Never That Easy-Reply. 用于晚期黑色素瘤定制治疗的 PD-L1 表达--绝非易事--回复。
IF 28.4 1区 医学
Jama Oncology Pub Date : 2024-11-07 DOI: 10.1001/jamaoncol.2024.4905
Marco Donia, Inge Marie Svane
{"title":"PD-L1 Expression for Tailoring Treatment in Advanced Melanoma-It Is Never That Easy-Reply.","authors":"Marco Donia, Inge Marie Svane","doi":"10.1001/jamaoncol.2024.4905","DOIUrl":"https://doi.org/10.1001/jamaoncol.2024.4905","url":null,"abstract":"","PeriodicalId":48661,"journal":{"name":"Jama Oncology","volume":" ","pages":""},"PeriodicalIF":28.4,"publicationDate":"2024-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142606997","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
PD-L1 Expression for Tailoring Treatment in Advanced Melanoma-It Is Never That Easy. 用于晚期黑色素瘤定制治疗的 PD-L1 表达--绝非易事。
IF 28.4 1区 医学
Jama Oncology Pub Date : 2024-11-07 DOI: 10.1001/jamaoncol.2024.4902
Latif Karahan, Mutlu Hayran, Omer Dizdar
{"title":"PD-L1 Expression for Tailoring Treatment in Advanced Melanoma-It Is Never That Easy.","authors":"Latif Karahan, Mutlu Hayran, Omer Dizdar","doi":"10.1001/jamaoncol.2024.4902","DOIUrl":"https://doi.org/10.1001/jamaoncol.2024.4902","url":null,"abstract":"","PeriodicalId":48661,"journal":{"name":"Jama Oncology","volume":" ","pages":""},"PeriodicalIF":28.4,"publicationDate":"2024-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142606995","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Efficacy of Adding Veliparib to Temozolomide for Patients With MGMT-Methylated Glioblastoma: A Randomized Clinical Trial. MGMT甲基化胶质母细胞瘤患者在替莫唑胺基础上加用Veliparib的疗效:随机临床试验
IF 28.4 1区 医学
Jama Oncology Pub Date : 2024-10-31 DOI: 10.1001/jamaoncol.2024.4361
Jann N Sarkaria, Karla V Ballman, Sani H Kizilbash, Erik P Sulman, Caterina Giannini, Bret B Friday, Nicholas A Butowski, Nimish A Mohile, David E Piccioni, James D Battiste, Jan Drappatz, Jian L Campian, Sandeep Mashru, Kurt A Jaeckle, Barbara J O'Brien, Jesse G Dixon, Brian F Kabat, Nadia L Laack, Leland S Hu, Timothy Kaufmann, Priya Kumthekar, Benjamin M Ellingson, S Keith Anderson, Evanthia Galanis
{"title":"Efficacy of Adding Veliparib to Temozolomide for Patients With MGMT-Methylated Glioblastoma: A Randomized Clinical Trial.","authors":"Jann N Sarkaria, Karla V Ballman, Sani H Kizilbash, Erik P Sulman, Caterina Giannini, Bret B Friday, Nicholas A Butowski, Nimish A Mohile, David E Piccioni, James D Battiste, Jan Drappatz, Jian L Campian, Sandeep Mashru, Kurt A Jaeckle, Barbara J O'Brien, Jesse G Dixon, Brian F Kabat, Nadia L Laack, Leland S Hu, Timothy Kaufmann, Priya Kumthekar, Benjamin M Ellingson, S Keith Anderson, Evanthia Galanis","doi":"10.1001/jamaoncol.2024.4361","DOIUrl":"10.1001/jamaoncol.2024.4361","url":null,"abstract":"<p><strong>Importance: </strong>The prognosis for patients with glioblastoma is poor following standard therapy with surgical resection, radiation, temozolomide, and tumor-treating fields.</p><p><strong>Objectives: </strong>To evaluate the combination of veliparib and temozolomide in glioblastoma based on preclinical data demonstrating significant chemosensitizing effects of the polyadenosine diphosphate-ribose polymerase 1/2 inhibitor veliparib when combined with temozolomide.</p><p><strong>Design, setting, and participants: </strong>Patients with newly diagnosed glioblastoma with MGMT promoter hypermethylation who had completed concomitant radiation and temozolomide were enrolled between December 15, 2014, and December 15, 2018, in this Alliance for Clinical Trials in Oncology trial. The data for this analysis were locked on April 21, 2023.</p><p><strong>Interventions: </strong>Patients were randomized and treated with standard adjuvant temozolomide (150-200 mg/m2 orally, days 1-5) combined with either placebo or veliparib (40 mg orally, twice daily, days 1-7) for 6 cycles.</p><p><strong>Main outcomes and measures: </strong>The primary end point for the phase 3 portion of the trial was overall survival (OS).</p><p><strong>Results: </strong>There were 322 patients randomized during the phase 2 accrual period and an additional 125 patients randomized to complete the phase 3 accrual, for a total of 447 patients in the final phase 3 analysis. The median (range) age for patients was 60 (20-85) years and 190 patients (42.5%) were female. The median OS was 24.8 months (90% CI, 22.6-27.7) for the placebo arm and 28.1 months (90% CI, 24.3-33.3) for the veliparib arm (P = .17). The difference in survival did not meet the prespecified efficacy end point. However, there was a separation of the survival curves that favored the veliparib arm over 24 to 48 months of follow-up. The experimental combination was well tolerated with an acceptable elevation in grade 3 or 4 hematologic toxic effects.</p><p><strong>Conclusions and relevance: </strong>This trial found that adding veliparib to adjuvant temozolomide did not significantly extend OS in patients with newly diagnosed, MGMT-hypermethylated glioblastoma.</p><p><strong>Trial registration: </strong>ClinicalTrials.gov Identifier: NCT02152982.</p>","PeriodicalId":48661,"journal":{"name":"Jama Oncology","volume":" ","pages":""},"PeriodicalIF":28.4,"publicationDate":"2024-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11528341/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142548405","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Errors in Figure 3. 图 3 中的错误。
IF 28.4 1区 医学
Jama Oncology Pub Date : 2024-10-31 DOI: 10.1001/jamaoncol.2024.5240
{"title":"Errors in Figure 3.","authors":"","doi":"10.1001/jamaoncol.2024.5240","DOIUrl":"https://doi.org/10.1001/jamaoncol.2024.5240","url":null,"abstract":"","PeriodicalId":48661,"journal":{"name":"Jama Oncology","volume":" ","pages":""},"PeriodicalIF":28.4,"publicationDate":"2024-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142548406","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
metastatic. 转移。
IF 28.4 1区 医学
Jama Oncology Pub Date : 2024-10-31 DOI: 10.1001/jamaoncol.2024.4899
Tega Ebeye
{"title":"metastatic.","authors":"Tega Ebeye","doi":"10.1001/jamaoncol.2024.4899","DOIUrl":"https://doi.org/10.1001/jamaoncol.2024.4899","url":null,"abstract":"","PeriodicalId":48661,"journal":{"name":"Jama Oncology","volume":" ","pages":""},"PeriodicalIF":28.4,"publicationDate":"2024-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142548409","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effects of the Oncology Industrial Complex on Academic Cancer Centers. 肿瘤学工业综合体对癌症学术中心的影响。
IF 28.4 1区 医学
Jama Oncology Pub Date : 2024-10-31 DOI: 10.1001/jamaoncol.2024.4876
S Gail Eckhardt, Leonidas C Platanias
{"title":"Effects of the Oncology Industrial Complex on Academic Cancer Centers.","authors":"S Gail Eckhardt, Leonidas C Platanias","doi":"10.1001/jamaoncol.2024.4876","DOIUrl":"https://doi.org/10.1001/jamaoncol.2024.4876","url":null,"abstract":"","PeriodicalId":48661,"journal":{"name":"Jama Oncology","volume":" ","pages":""},"PeriodicalIF":28.4,"publicationDate":"2024-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142548404","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信